In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Aerie Pharma (AERI – Research Report), with a price target of $20.00. The company's shares closed last Friday at $6.25, close to its 52-week low of $5.46. According to TipRanks.com, Livnat has 0 stars on 0-5 stars ranking scale with an average return of -3.3% and a 39.5% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Verrica Pharmaceuticals, and Satsuma Pharmaceuticals. Currently, the analyst consensus on Aerie Pharma is a Strong Buy with an average price target of $18.00, implying a 129.9% upside from current levels.
https://www.tipranks.com/news/blurbs/aerie-pharma-aeri-gets-a-buy-rating-from-h-c-wainwright-2?utm_source=advfn.com&utm_medium=referral